Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3475

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Nanobiotix signs €40m deal with the EIB

loan to fund innovative nanomedicine platform

- PMLiVE

Some pharma companies not prepared for Brexit, warns EMA

Regulator concerned about medicines shortages after March 2019

SWITCHED ONcology Patient Experience Focus Group Full Discussion

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...

Havas Lynx

SWITCHED ONcology Patient Experience Focus Group Highlights

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. "We...

Havas Lynx

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links